Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo

Having agreed on a collaborative deal, Agenus Inc (NASDAQ:AGEN) and National Cancer Institute (NCI) will work together in evaluating Agenus’ personalized autologous vaccine candidate, Prophage (HSPPC-96). MRK PD-1 therapy, Keytruda from Merck & Co., Inc.(NYSE:MRK) will also be incorporated. Merck’s inclusion comes on the back of its incredible performance in the past year having recorded a rise in the stock of 19.7%.

The evaluation will be seeking the role of Prophage in conjunction with Keytruda in patients who have been diagnosed with glioblastoma (ndGBM). The phase II study will evaluate the efficacy of a PD-1 targeted checkpoint blockade. A heat shock protein-based vaccine candidate will also be used in this trial.

researching, researcher, research, medical, lab, health, electronic, technician, screen, specialist, woman, man, serious, studying, table, surgical glasses, practitioner, male,

wavebreakmedia/Shutterstock.com

Notable Efforts By Agenus To Form Collaborations

The study will have two arms. One will involve receiving Keytruda as monotherapy while the other will be receiving the Prophage-Keytruda combination. Apparently, Agenus Inc (NASDAQ:AGEN) has been on record in the recent past for its efforts to boost its pipeline. It has been soliciting for collaborations that are in line with its agenda and it will not only provide technology but also financial resources. Nonetheless, in the recent wave of competition in the pharmaceutical industry, the efforts are acknowledged.

But there is a challenge. There is no approved product in its portfolio, a situation that makes it dependent on its partners for pipeline development. This is to some extent a tall order if it has to deliver its objectives because it means it is likely to take a couple of years before it can launch an independent product.

Agenus Inc (NASDAQ:AGEN) is in competition with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Anika Therapeutics Inc (NASDAQ:ANIK), which sport a Zacks Rank #1, a strong buy. Both Sucampo and Anika posted impressive earnings with the former having an increase from $1.30 to $1.74 per share for 2017 within 60 days with an average beat of 35.5%. The latter’s average beat was 33.14%.

Meanwhile, Agenus stock was trading at $4.00, an increase of $0.05 or 1.27%.

Follow Agenus Inc (NASDAQ:AGEN)
Trade (NASDAQ:AGEN) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.